Uveal Melanoma and Brachytheraphy: Long-term Outcomes.

Long-term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04577742

Enrollment

350

Registered

2020-10-08

Start date

2011-02-01

Completion date

2020-03-30

Last updated

2020-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

106 Ruthenium Plaque Brachytherapy, Uveal Melanoma

Brief summary

This study investigated the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival in patients affected by uveal melanoma and undergoing Ru-106 plaque brachytherapy between February 2011 and March 2020

Interventions

RADIATION106 Ruthenium plaque brachytherapy

All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Inclusion criteria

* age older than 40 years * diagnosis of uveal melanoma

Exclusion criteria

* age older than 80 years * No diagnosis of uveal melanoma

Design outcomes

Primary

Measure	Time frame	Description
To evaluate long-term outcomes in patients underwent brachytherapy for uveal melanoma	Mean follow-up was 4 years (3 months-9 years)	To investigate the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026